Biotech & Life Sciences

In the fast pace industries that surround Biotechnologies an IT provider must be agile and scalable. At K&R Network Solutions we deliver IT for our clients to succeed in their respective Life Science endeavors.

Whether clinical trials, R&D or production is your core business focus K&R Network Solutions provides all encompassing IT services, support and infrastructure. We have the foresight and experience with fast growing companies and are prepared to handle all aspects of technology along the way.

In addition to the core IT services, K&R Network Solutions offers assistance with SOPs pertaining to technology. Our clients gain a tremendous resource with our experienced IT Advisors on their team.

Document tracking, version control and auditing is a key component to many regulations and K&R Network Solutions provides solutions and the experience to be successful. A Document Management System will address all aspects of your business process, development cycle and be capable of handling any number of advanced integration needs.

There are many third party products that require special attention for success. Microsoft’s Sharepoint technologies should be closely evaluated before any business decision is made. Contact K&R Network Solutions today to fulfill your key role of Information Technology.

Quick Links

Recent Testimonial

K&R Network Solutions has been instrumental in the growth of our Company from inception to today. They have completely designed our network from workstation and network planning to software and security. K&R Network Solutions has helped manage the growth of our employee and client base, and monitors all of our systems 24 hours a day, 7 days a week. We are so confident in the work that they have provided for us, that we have referred them to a number of companies in the financial services industry. Throughout the K&R Network Solutions organization, they have treated us like one of their most valued customers, and we recommend reviewing their offering and suite of services in detail.
Callan Capital